The US regulators have been particularly focused on new players in the health tech space and the novel regulatory issues their products present within the existing legal framework. While the market is ripe with opportunity for innovative healthcare delivery models, tech companies should proceed with caution and ensure they understand the complex rigors and requirements of US healthcare regulations and enforcement regimes.
In this episode of our Connected With Latham podcast series, Washington D.C. See more +
The US regulators have been particularly focused on new players in the health tech space and the novel regulatory issues their products present within the existing legal framework. While the market is ripe with opportunity for innovative healthcare delivery models, tech companies should proceed with caution and ensure they understand the complex rigors and requirements of US healthcare regulations and enforcement regimes.
In this episode of our Connected With Latham podcast series, Washington D.C. partner John Manthei, Global Chair of the Healthcare & Life Sciences Practice, speaks with Terra Reynolds, Global Vice Chair of the firm's Healthcare & Life Sciences Industry Group, and David Tolley, Chair of the firm’s Litigation & Trial Department in Boston, about the regulatory risks for tech companies transitioning to healthcare. See less -
